McKesson Corporation
Healthcare Distribution and TechnologyFounded 1833- Updated June 2025
Reviewed by Swet Parvadiya
Last reviewed: June 2025
CorpDigest
McKesson Corporation
Financial Performance
Last reviewed: June 2025 · By Swet Parvadiya
Revenue
$308.9B
Market Cap
$80.0B
Net Income
$3.1B
Employees
51,000
Revenue grew from $276.4 billion in FY2022 to $312.8 billion in FY2023, then contracted slightly to $308.95 billion in FY2024. The FY2023 peak reflects a combination of pharmaceutical price inflation and volume growth; the FY2024 contraction reflects normalization. On revenues of nearly $309 billion, net income was $3.146 billion — a margin of approximately 1%. That margin is typical for pharmaceutical distribution and reflects the structural reality of operating as an intermediary between powerful manufacturers with pricing leverage and pharmacy chains with their own negotiating scale. Market capitalization of $80 billion on $309 billion in revenue implies a significant premium to the thin-margin distribution business, which is justified by the higher-margin healthcare technology and oncology services segments that have growing revenue contributions. The $6.5 billion in free cash flow generated in FY2024 is the financial metric that explains the market premium: McKesson generates exceptional cash flow relative to its net income because the working capital dynamics of distribution — collecting receivables faster than paying payables — are favorable. The opioid litigation settlement of approximately $8.1 billion, paid over 18 years, is a recurring charge that continues running through the income statement. The Change Healthcare cyberattack in 2024 created operational disruption and financial liability that have not yet been fully quantified in public disclosures. McKesson deployed approximately $1.0 billion in R&D in FY2024, an unusually high figure for a distributor that reflects the technology-intensive nature of its expanded healthcare services operations. The strategic bet — that McKesson can command higher margins by embedding software and analytics into its distribution relationships — depends on continued investment in these capabilities.
Revenue Trend Analysis
YoY Change
-1.2%
2-Year CAGR
+5.7%
Peak Year
2023
Trend
Mostly Growing
McKesson Corporation has reported revenue across 3 fiscal years, compounding at +5.7% annually over 2 years. The most recent year saw a 1.2% decline versus the prior year. Revenue peaked in 2023 at $312.8B. Out of 2 reported periods, 1 showed growth and 1 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2024 | $309.0B | $3.1B | -1.2% |
| FY2023 | $312.8B | — | +13.2% |
| FY2022 | $276.4B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
McKesson's revenue is dominated by pharmaceutical drug cost pass-through. When McKesson sells a $1,000 branded drug to a pharmacy, that $1,000 appears as revenue, but McKesson paid approximately $990–$995 for it. The $5–$10 gross profit on that transaction is a thin but real return on an enormous volume. FY2024 revenue was $308.9 billion, but operating income is measured in the low single-digit billions rather than tens of billions. McKesson's operating margins are approximately 1.5–2.0%, making it a very-high-revenue, lower-margin business by absolute percentage standards. However, the absolute dollar profit is substantial enough to fund significant share repurchases, dividends, and capital investment. McKesson generated approximately $2.3 billion in adjusted operating profit in FY2024. The company's return on equity is very high because it operates with negative working capital (pharmacies pay McKesson quickly while McKesson has payment terms with manufacturers), allowing it to earn high returns on relatively modest equity investment. This negative-working-capital dynamic is a significant, underappreciated aspect of the distribution business model.
McKesson's revenue has grown substantially over the past decade, driven primarily by drug price inflation (branded pharmaceuticals) and volume growth (an aging population filling more prescriptions). FY2022 revenue was $276.4 billion, FY2023 was $312.8 billion, and FY2024 was $308.9 billion. The slight decline from FY2023 to FY2024 reflects branded drug pricing dynamics and some volume mix changes. The longer-term driver is the specialty pharmaceutical market: GLP-1 drugs like Ozempic and Wegovy, oncology biologics, and rare disease therapies carry high average selling prices that inflate McKesson's revenue even at thin margins. When a $30,000-per-month rare disease therapy flows through McKesson's distribution network, it contributes far more to revenue than generic ibuprofen. This drug-price inflation has been the primary growth engine alongside prescription volume growth from the aging U.S. population. Generic drug price deflation is a headwind: when generic prices fall, the same prescription volume produces less revenue. McKesson partially mitigates this through its generic purchasing joint ventures.
McKesson has been an aggressive returner of capital to shareholders, enabled by its negative-working-capital distribution model. The company generated substantial free cash flow even after the $13.8 billion opioid settlement commitments. Capital allocation priorities are: (1) Share repurchases — McKesson has reduced its share count dramatically over the past decade through buybacks funded by operating cash flow. The shrinking share count amplifies earnings-per-share growth even when absolute net income is relatively flat. (2) Dividends — McKesson maintains a dividend, though buybacks dwarf dividend payouts as a cash return mechanism. (3) Acquisitions — McKesson makes targeted acquisitions in specialty distribution and healthcare technology rather than large transformative deals. The US Oncology ($2.0B) and RelayHealth ($1.2B) acquisitions exemplify this approach: adding capabilities or market position in higher-margin adjacent areas. (4) Opioid settlement payments — over the 18-year settlement period, McKesson must make structured payments that constrain but don't eliminate capital return capacity. The disciplined buyback program has been the primary driver of McKesson's stock performance over the past decade.
The three major U.S. pharmaceutical distributors — McKesson, Cencora (formerly AmerisourceBergen), and Cardinal Health — have similar operating models but different strategic emphases. McKesson is the largest by total revenue ($308.9B in FY2024) and has invested most aggressively in specialty oncology distribution through US Oncology. Cencora ($262.2B in revenue) has the deepest relationship with AbbVie's specialty pharmacy network and the biotech distribution market. Cardinal Health ($202B) has diversified more into medical products distribution and had a major pharmacy segment that it spun off in 2022. McKesson's competitive position is strongest in community oncology (US Oncology network), independent pharmacy (Health Mart), and healthcare technology. All three companies face similar long-term structural issues: drug price transparency legislation that could compress margins, branded-to-generic conversion that reduces per-unit value, and the ongoing opioid settlement obligations. McKesson's scale advantage in oncology specialty distribution is its most defensible differentiator versus peers.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "McKesson Corporation Revenue & Financials." CorpDigest, https://corpdigest.com/company/mckesson/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>McKesson Corporation reported $309B in revenue (FY2024).</strong><br>Source: <a href="https://corpdigest.com/company/mckesson/financials" target="_blank" rel="noopener">CorpDigest — McKesson Corporation financials</a></div>